Practical Neurology

February 2020

Multiple Sclerosis: Reverse Engineering Continues

Featured

The Central Vein Sign

Evanthia Bernitsas, MD

Point/Counterpoint: Neurofilament Light

Adil Javed, MD, PhD; and James Stankiewicz MD, FAAN

Sphingosine-1-Phosphate Modulators for Multiple Sclerosis

Mark B. Skeen, MD

AntiCD20+ Agents

Brian Barry, MD; and Robert K. Shin, MD

Cladribine

Crystal Dixon, MD; Miguel Melo-Bicchi, MD; and Kottil W. Rammohan, MD

Drugs in Development for Multiple Sclerosis

Konstantin Balashov, MD, PhD

Point/Counterpoint: Food and Drug Administration Multiple Sclerosis Categorization Changes

Svetlana Primma Eckert, MD; Bianca Weinstock-Guttman, MD; and Stephen Krieger, MD

Multiple Sclerosis Treatment in Racial and Ethnic Minorities

Michael V. Robers, MD; Deepak Soneji, MD, PhD; and Lilyana Amezcua, MD, MS

In this issue

Guest Medical Editor's Page

Multiple Sclerosis: Reverse Engineering Continues

Thomas P. Leist, MD

Cover Focus

The Central Vein Sign

Is 1.5 T MRI still relevant for diagnosis of multiple sclerosis?

Evanthia Bernitsas, MD

Point/Counterpoint: Neurofilament Light

Ready for prime time as a biomarker for multiple sclerosis or not?

Adil Javed, MD, PhD; and James Stankiewicz MD, FAAN

Sphingosine-1-Phosphate Modulators for Multiple Sclerosis

Sphingosine-1-phosphate modulators may act through more than just inhibition of neuroimmune and neuroinflammatory effects of multiple sclerosis.

Mark B. Skeen, MD

AntiCD20+ Agents

AntiCD20+ agents are among the highest efficacy treatments for multiple sclerosis.

Brian Barry, MD; and Robert K. Shin, MD

Cladribine

Cladribine is an effective oral treatment for multiple sclerosis with potential for long-term remission.

Crystal Dixon, MD; Miguel Melo-Bicchi, MD; and Kottil W. Rammohan, MD

Drugs in Development for Multiple Sclerosis

Stem cells, tyrosine kinase inhibitors, remyelinating agents, metabolically active molecules, and more are being tested as potential new disease-modifying treatments.

Konstantin Balashov, MD, PhD

Point/Counterpoint: Food and Drug Administration Multiple Sclerosis Categorization Changes

Are the changes a step forward or a step back?

Svetlana Primma Eckert, MD; Bianca Weinstock-Guttman, MD; and Stephen Krieger, MD

Multiple Sclerosis Treatment in Racial and Ethnic Minorities

Systematic literature review shows little evidence to guide treatment.

Michael V. Robers, MD; Deepak Soneji, MD, PhD; and Lilyana Amezcua, MD, MS

Special Report

Long-Term Survival Prognosis After Stroke

A practical guide for clinicians.

Robert Shavelle, PhD, FAACPDM; Jordan Brooks, PhD, MPH; David Strauss, PhD, FASA; and Amytis Towfighi, MD

Columns

Headache Horizons: Headaches That Roam the Night

Many headache types can occur in the night, including some that may be exclusive to dream periods.

Peter McAllister, MD

Neuromuscular Notes: Taking the Mis- out of CIDP Diagnosis

Criteria exist for CIDP and should be used for diagnosis and management.

Karissa Gable, MD

Smart Business Great Medicine: Patient Engagement

Let’s make engaging patients worth doing.

James Geyer, MD; and Jenna Cooper, CRNP

About The Cover Artist

An Example of the Central Vein Sign

Daniel S. Reich, MD, PhD

Read Issue

Patients & Caregivers

Find Information and tools about Neurological diseases to assist patients and caregivers.

Visit Page

Students & Residents

Valuable insights and advice for future neurologists.

Visit Page

Case Reports